A 2021 study [116] evaluating the clinical efficacy of anti‐PD‐(L)1 treatment in 98 patients with coexisting malignant tumors and different TB statuses found that the objective response rates for patients with active PTB, LTBI, and obsolete PTB receiving immunotherapy were all greater than 70% (p > 0.005). Here, CD274 is linked to cancer.